CI Price Prediction Next Week
Technical Analysis: Based on recent price action, CI has shown a bearish trend after dropping significantly due to Trump's executive order on healthcare price transparency. The stock fell 2.27% to $306.77 on February 26th.
Fundamental Analysis: The Cigna Group received a high rating of 85% from Validea's Shareholder Yield Investor model, indicating strong fundamentals in the Healthcare Facilities industry. The company has been focusing on returning cash to shareholders through dividends, buybacks, and debt paydown.
News Impact: A major bearish catalyst emerged when President Trump signed an executive order on February 25th directing federal agencies to enforce and expand the 2019 rule requiring hospitals and insurers to publicly disclose actual medical service costs. This raised concerns about potential revenue impacts for healthcare companies.
Price Prediction for Next Week (March 4-8):
Bearish Factors:
- Renewed regulatory pressure from Trump's executive order
- Healthcare sector-wide weakness due to price transparency initiatives
- Senator Grassley pushing for greater oversight of Medicare Advantage plans
Support Levels:
- $290 (based on recent options activity)
- $285 (technical support)
Resistance Levels:
- $310 (recent resistance level)
- $315 (psychological resistance)
Forecast: Given the significant regulatory headwinds and sector-wide pressure, CI is likely to continue its downward trend next week. Price target: $285-295 range.
Recommendation: SELL
- Entry: Current market price (~$305)
- Target: $285
- Stop loss: $315
CI Similar Chart Price Prediction
The price of CI is predicted to go up -17.64%, based on the high correlation periods with JBL. The similarity of these two price pattern on the periods is 92.48%.
CI
JBL
Down: -17.64%Similarity: 92.48%
CI Revenue Forecast
CI EPS Forecast
CI FAQs
What is CI revenue forecast for next quarter？
What is CI eps forecast for next quarter？
CI VS S&P500
Combining with Express Scripts gave Cigna more tools to help clients control their healthcare costs, and we see significant cross-selling opportunities across their respective books of business.
With its strong medical cost trend history and goal to reduce that trend to the low-single-digits, Cigna should be able to benefit from continued enrollment gains in the more profitable commercial segment.
Cigna's organic earnings growth prospects look solid both with and without capital-allocation activities, such as share repurchases.
CI Analyst's Forecast
David Macdonald
Truist Securities
Strong Buy
2025-02-04
Price Target
$390 → $375
Upside
+27.85%
Truist lowered the firm's price target on Cigna to $375 from $390 and keeps a Buy rating on the shares. The firm is adjusting its model after the company's Q4 earnings miss, also cutting its FY25 EPS view to $29.58 from $31.40 and its FY26 view to $33.10 from $35.14, the analyst tells investors in a research note.
Michael Wiederhorn
Oppenheimer
Buy
2025-01-31
Price Target
$400 → $375
Upside
+27.46%
Raj Kumar
Stephens & Co.
Buy
2025-01-31
Price Target
$410 → $380
Upside
+29.16%
